Tandem Labs Offers GLP Assay Services

Tandem Laboratories is offering Good Laboratory Practices (GLP) compliant assay services using BioVeris Corp.’s products. Tandem acquired the BioVeris’ M-Series Analyzer, reagents and BioVerification training to expand their offering of assay technologies for biopharmaceutical and pharmaceutical customers. Tandem added the new methods to offer greater sensitivity, range and drug tolerance for GLP- compliant immunogenicity.

Tandem’s vice president and general manager of the biomarker and immunoanalytical division, Ira DuBey, said, “We chose BioVeris’ assay platform to complement our other methodologies for its advantages in assay performance, especially in pharmacokinetic and immunogenicity assays. Today, many more of our clients ask for BioVeris’ ECL detection for their assays, and Tandem Laboratories is focused on delivering the highest quality testing coupled with customized service to our clients.”

BioVeris’ chief executive officer, Samuel Wohlstadter, said, “We are pleased that Tandem Laboratories is the first CRO to adopt the M-SERIES platform for bioanalytical testing. We welcome Tandem as an experienced and well trained company that can support life science customers.”

With the increased number of biopharmaceutical products on the market, the two companies believe that immunogenicity testing will become a large percentage of pharmaceutical drug development tests.